Follistatin 344

Follistatin 344 (FS344) is a recombinant isoform derived from the human FST gene. It works as a high‑affinity binding protein for myostatin, activins, and selected BMP‑family ligands, effectively reducing signals that normally limit muscle growth Biological Activity of Follistatin Isoforms and Follistatin-Like-3 Is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin, and Bone Morphogenetic Proteins+1.

The peptide has mainly been studied in animal models for its ability to increase muscle mass and alter body composition.

Current interest centers on muscle‑wasting conditions, performance, and regenerative medicine, though human data remain indirect.

Follistatin 344 acts as a ligand trap outside cells. It binds myostatin and activins, preventing them from engaging activin type II receptors and reducing SMAD2/3 signals that normally put the brakes on muscle growth Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance+1.

Because follistatin is not selective for myostatin alone, it also affects activin pathways tied to metabolism, inflammation, and tissue repair.

Beyond muscle

A note on cancer risk

Because follistatin removes growth restraints, long‑term exposure could theoretically support tumor growth in susceptible tissues Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance+1. This is not proven for FS344, but it underscores why research protocols use short cycles with monitoring.

The strongest evidence for Follistatin 344 comes from animal and transgenic models.

In humans, the picture is indirect.

Documented outcomes

Community reports often mention faster recovery, muscle fullness, and modest strength gains over 2–4‑week cycles, but these are not backed by controlled human data (community protocol).

There are no published human dosing trials for exogenous Follistatin 344, so protocols come from animal work and community practice. Most research‑oriented cycles use subcutaneous injection with short durations to limit unknown long‑term risks.

Community‑derived research protocols

Protocol	Dose	Frequency	Duration	Notes
Tolerance assessment	50–100 mcg	Once daily	3–7 days	Titrate up based on response
Standard muscle‑gain	100–200 mcg	Once daily	10–30 days	Often used with training
Aggressive recomp	200–300 mcg	Once daily	20–30 days	Higher risk of side effects
Stacked with exercise	100–200 mcg	Once daily (post‑workout)	4–6 weeks	Exercise + EAA improves follistatin/myostatin ratio [source:1]

Supporting human evidence

This suggests that natural follistatin upregulation can benefit muscle, but it does not validate exogenous FS344.

Because product purity is inconsistent in non‑regulated markets Detection of Black Market Follistatin 344+1, any laboratory investigation should verify the peptide’s identity before use.

Pharmacologic interactions

Supplement interactions

• Creatine: May amplify rapid strength gains; monitor for disproportionate tendon stress.
• Insulin‑sensitizing herbs (berberine, ALA): Additive glucose‑lowering effects possible.

Condition‑specific cautions

• Active malignancy or cancer history: avoid due to growth‑signal modulation Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance+1.
• Diabetes or insulin resistance: use only with close glucose monitoring.
• Pregnancy/fertility treatment: avoid; follistatin has reproductive roles Exercise mimetics: molecular mechanisms, biological and therapeutic effects.

Follistatin 344 is often combined with other agents to amplify anabolic signals while counteracting different growth‑limiting pathways.

Common research stacks

• GH secretagogues (CJC‑1295, ipamorelin, MK‑677): FS344 removes myostatin‑mediated inhibition, while GH‑pathway compounds increase systemic IGF‑1. This dual approach may yield greater lean mass gains than either alone, but water retention and glucose control should be monitored Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance+1.
• BPC‑157 / TB‑500: Mechanistically distinct repair peptides; stacking aims to support recovery and soft‑tissue health alongside the muscle‑building effects of FS344. Evidence is low, but practitioner consensus considers it a safe‑bets approach.
• IGF‑1 LR3: Direct anabolic drive combined with myostatin antagonism. High risk of excessive growth and metabolic strain; requires conservative dosing and monitoring.
• During weight loss (GLP‑1 agonists): FS344 may help preserve lean mass in a calorie deficit, but glycemic interactions are complex and require vigilant tracking Follistatin and Follistatin Like‐3 Differentially Regulate Adiposity and Glucose Homeostasis+1.

Stacking rationale

Because FS344 works by lowering anti‑growth signals rather than boosting anabolic hormones directly, it pairs naturally with agents that increase protein synthesis or recovery. The main risk is pushing muscles faster than tendons and metabolic regulation can adapt.

Follistatin 344 is not approved by the FDA or any major regulatory body for human use. It is sold as a research chemical, and analytical testing has shown that black‑market products often contain mislabeled or adulterated material Detection of Black Market Follistatin 344+1.

Anti‑doping

Follistatin is explicitly prohibited by WADA under category S4 (hormone and metabolic modulators) at all times. A detection method exists that can distinguish His‑tagged recombinant FS344 from endogenous follistatin Detection of Black Market Follistatin 344+1. Athletes subject to doping control should consider any use a high‑risk violation.

Legal status

• United States: Not an FDA‑approved drug; no DEA scheduling, but unapproved peptides are legally gray. Customs seizure is possible.
• International: Not approved as a medicine by EMA, MHRA, or TGA. Personal import limits vary, but the product is typically treated as an unlicensed pharmaceutical.

The safest legal path is to treat FS344 as an investigational compound with no established regulatory pathway for consumer use.

Human safety data for Follistatin 344 are extremely limited, so risk assessment relies on mechanism, animal data, and small case series.

Documented adverse events

• Metabolic instability: Observational data associate elevated follistatin with worse glycemic control in some populations Elevated Circulating Follistatin Is Associated With Diabetic Status and Glycemic Dysregulation in Patients With β‐Thalassemia Major. Monitoring fasting glucose and HbA1c is prudent.
• Product quality: Over half of tested black‑market samples did not contain actual follistatin, and some included other growth‑promoting peptides Detection of Black Market Follistatin 344+1. Toxicity from contaminants is a real risk.

Theoretical concerns

• Cancer: Long‑term myostatin/activin blockage could remove growth restraints in susceptible tissues Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance+1. Avoid in anyone with cancer history or surveillance.
• Reproductive effects: Follistatin plays roles in ovarian, placental, and testicular biology. No data exist for FS344 in pregnancy or fertility contexts.
• Fibrosis: Modulating TGF‑β pathways may unpredictably affect wound healing or existing fibrotic conditions Deletion of fibro-adipogenic progenitors-specific follistatin impairs muscle function and accelerates skeletal muscle atrophy in obese mice+1.

Contraindications

• Active malignancy or recent cancer treatment
• Pre‑existing retinal disease or central serous chorioretinopathy
• Use of unverified, black‑market material without analytical confirmation
• Pregnancy or breastfeeding
• Uncontrolled diabetes or insulin resistance without medical oversight